Advertisement

World Journal of Surgery

, Volume 42, Issue 8, pp 2617–2626 | Cite as

Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma in Elderly Patients: Special Reference to Postoperative Adjuvant Chemotherapy

  • Yusuke Watanabe
  • Tomohiko Shinkawa
  • Sho Endo
  • Yuji Abe
  • Kazuyoshi Nishihara
  • Toru Nakano
Original Scientific Report
  • 75 Downloads

Abstract

Background

The benefit of pancreatectomy for elderly patients with pancreatic ductal adenocarcinoma (PDAC) remains controversial. Moreover, adjuvant chemotherapy (AC) for elderly patients has not been fully evaluated. We investigated the long-term outcomes after pancreatectomy for PDAC in elderly patients with special reference to AC.

Methods

The medical records of 123 patients who underwent pancreatectomy for PDAC from 2007 to 2016 were retrospectively reviewed. The patients were divided into two groups: young (<75 years) and elderly patients (≥75 years).

Results

The study population comprised 91 young and 32 elderly patients. The postoperative clinical courses were not different between the two groups. AC was more frequently administered to young (85%) than elderly patients (66%; P = 0.04). The weekly dose of tegafur/gimeracil/oteracil potassium (S1) for AC was significantly lower in elderly (median 423 mg/m2) than young patients (median 491 mg/m2; P = 0.02). The prevalence of adverse events and the completion rate of AC were not significantly different between the two groups. There were no significant differences in recurrence-free survival (P = 0.73) or overall survival (P = 0.68) between the two groups in univariate analysis. Receipt of AC was not a significant independent factor for survival, and completion of planned AC was a significant independent factor for recurrence-free survival and overall survival in multivariate analysis.

Conclusions

The benefit of pancreatectomy for PDAC was the same between young and elderly patients. Completion of planned AC was important, and lowered-dose AC using S1 for elderly patients might be safe and therapeutically useful.

Notes

Acknowledgements

We thank Angela Morben, DVM, ELS, from Edanz Group (www.edanzediting.com/ac), for editing a draft of this manuscript.

Authors’ contributions

YW drafted the manuscript. YW, TS, and SE contributed to the creation of the database of the study population and performed the data extraction and analysis. YW and KN contributed to the study conception and design. YW, YA, and KN performed the pancreatectomy and followed up the study population. YA and KN contributed to the interpretation of the results and revision of the manuscript. All authors discussed the results and commented on the manuscript. TN gave final approval of this article.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

References

  1. 1.
    Shamali A, De’Ath HD, Jaber B et al (2017) Elderly patients have similar short term outcomes and five-year survival compared to younger patients after pancreatoduodenectomy. Int J Surg 45:138–143CrossRefPubMedGoogle Scholar
  2. 2.
    Sugiura T, Okamura Y, Ito T et al (2017) Impact of patient age on the postoperative survival in pancreatic head cancer. Ann Surg Oncol 24:3220 (in press) CrossRefPubMedGoogle Scholar
  3. 3.
    Ferrone CR, Brennan MF, Gonen M et al (2008) Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 12:701–706CrossRefPubMedGoogle Scholar
  4. 4.
    Dusch N, Weiss C, Strobel P et al (2014) Factors predicting long-term survival following pancreatic resection for ductal adenocarcinoma of the pancreas. J Gastrointest Surg 18:674–681CrossRefPubMedGoogle Scholar
  5. 5.
    Nathan H, Wolfgang CL, Edil BH et al (2009) Peri-operative mortality and long-term survival after total pancreatectomy for pancreatic adenocarcinoma: a population-based perspective. J Surg Oncol 99:87–92CrossRefPubMedGoogle Scholar
  6. 6.
    Katz MH, Wang H, Fleming JB et al (2009) Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16:836–847CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Han SS, Jang JK, Kim SW et al (2006) Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 32:271–275CrossRefPubMedGoogle Scholar
  8. 8.
    Bathe OF, Levi D, Caldera H et al (2000) Radical resection of periampullary tumors in the elderly: evaluation of long-term results. World J Surg 24:353–358CrossRefPubMedGoogle Scholar
  9. 9.
    Renz BW, Khali PN, Mikhailov M et al (2016) Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head is justified in elderly patients: a retrospective cohort study. Int J Surg 28:118–125CrossRefPubMedGoogle Scholar
  10. 10.
    Marmor S, Burke EE, Virnig BA et al (2016) A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas. Cancer 122:3378–3385CrossRefPubMedGoogle Scholar
  11. 11.
    Oliveira-Cunha M, Malde DJ, Aldouri A et al (2013) Results of pancreatic surgery in the elderly: is age a barrier? HPB (Oxford) 15:24–30CrossRefGoogle Scholar
  12. 12.
    Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 293:267–277CrossRefGoogle Scholar
  13. 13.
    Uesaka K, Boku N, Fukutomi A et al (2016) Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomized, non-inferiority trial (JASPAC 01). Lancet 388:248–257CrossRefPubMedGoogle Scholar
  14. 14.
    Watanabe Y, Nishihara K, Matsumoto S et al (2017) Effect of postoperative major complications on prognosis after pancreatectomy for pancreatic cancer: a retrospective review. Surg Today 47:555–567CrossRefPubMedGoogle Scholar
  15. 15.
    Shiroyama T, Kijima T, Komuta K et al (2012) Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer. Cancer Chemother Pharmacol 70:783–789CrossRefPubMedGoogle Scholar
  16. 16.
    Miura F, Yamamoto M, Gotoh M et al (2016) Validation of the board certification system for expert surgeons (hepato-biliary-pancreatic field) using the data of National Clinical Database of Japan: part 2 -pancreatoduodenectomy. J Hepatobiliary Pancreat Sci 23:353–363CrossRefPubMedGoogle Scholar
  17. 17.
    Sobin L, Gospodarowics M, Wittekind C (2009) TNM classification of malignant tumor, 7th edn. Wiley, New YorkGoogle Scholar
  18. 18.
    Bassi C, Dervenis C, Butturini G et al (2005) Postoperative pancreatic fistula: an international study group (ISGPS) definition. Surgery 138:8–13CrossRefPubMedGoogle Scholar
  19. 19.
    Wente MN, Veit JA, Bassi C et al (2007) Postoperative hemorrhage (PPH): an international study group of pancreatic surgery (ISGPS) definition. Surgery 142:20–25CrossRefPubMedGoogle Scholar
  20. 20.
    Clavien PA, Barkun J, de Oliveira M et al (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250:187–196CrossRefPubMedGoogle Scholar
  21. 21.
    Rail TS, Reddy DM, Nealon WH et al (2008) The effect of age on short-term outcomes after pancreatic resection: a population-based study. Ann Surg 248:109–117Google Scholar
  22. 22.
    Adham M, Bredt LC, Robert M et al (2014) Pancreatic resection in elderly patients: should it be denied? Langenbecks Arch Surg 399:449–459CrossRefPubMedGoogle Scholar
  23. 23.
    Lee DY, Schwartz JA, Wexelman B et al (2014) Outcomes of pancreaticoduodenectomy for pancreatic malignancy in octogenarians: an American College of Surgeons National Surgical Quality Improvement Program analysis. Am J Surg 2014:540–543CrossRefGoogle Scholar
  24. 24.
    Gooiker GA, Lemmens VE, Besseling MG et al (2014) Impact of centralization of pancreatic cancer surgery on resection rates and survival. Br J Surg 101:1000–1005CrossRefPubMedGoogle Scholar
  25. 25.
    Yoshioka R, Yasunaga H, Hasegawa K et al (2014) Impact of hospital volume on hospital mortality, length of stay and total costs after pancreaticoduodenectomy. Br J Surg 101:523–529CrossRefPubMedGoogle Scholar
  26. 26.
    Rutter CE, Parks HS, Corso CD et al (2015) Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: an analysis of the National Cancer Data Base. Cancer 121:4141–4149CrossRefPubMedGoogle Scholar
  27. 27.
    Neoptolemos JP, Stocken DD, Bassi C et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304:1073–1081CrossRefPubMedGoogle Scholar
  28. 28.
    Yamaguchi K, Okusaka T, Shimizu K et al (2014) EBM-based clinical guidelines for pancreatic cancer (2013) issued by the Japan Pancreas Society: a synopsis. Jpn J Clin Oncol 44:883–888CrossRefPubMedGoogle Scholar
  29. 29.
    Kinoshita S, Sho M, Yanagimoto H et al (2015) Potential role of surgical resection for pancreatic cancer in the very elderly. Pancreatology 15:240–246CrossRefPubMedGoogle Scholar
  30. 30.
    Yamanaka T, Matsumoto S, Teramukai S et al (2007) Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer. Gastric Cancer 10:129–134CrossRefPubMedGoogle Scholar
  31. 31.
    Ravikumar R, Sabin C, Abu Hilal M et al (2014) Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study. J Am Coll Surg 218:401–411CrossRefPubMedGoogle Scholar
  32. 32.
    Nakao A, Kanzaki A, Fujii T et al (2012) Correlation between radiographic classification and pathological grade of portal vein wall invasion in pancreatic head cancer. Ann Surg 255:103–108CrossRefPubMedGoogle Scholar
  33. 33.
    Yekebas EF, Bogoevski D, Cataldegirmen G et al (2008) En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients. Ann Surg 247:300–309CrossRefPubMedGoogle Scholar
  34. 34.
    Assifi MM, Lu X, Eibl G et al (2011) Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 150:466–473CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Laurence JM, Tran PD, Morarji K et al (2011) A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg 15:2059–2069CrossRefPubMedGoogle Scholar
  36. 36.
    Motoi F, Ishida K, Fujishima F et al (2013) Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol 20:3794–3801CrossRefPubMedGoogle Scholar
  37. 37.
    Sezai A, Osaka S, Yaoita H et al (2015) Long-term outcome of prosthetic valve replacement in Japanese patients aged 65 years or older: are Guidelines for prosthetic valve selection based on overseas data appropriate for Japanese patients? Ann Thorac Cardiovasc Surg 21:254–260CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2018

Authors and Affiliations

  • Yusuke Watanabe
    • 1
  • Tomohiko Shinkawa
    • 1
  • Sho Endo
    • 1
  • Yuji Abe
    • 1
  • Kazuyoshi Nishihara
    • 1
  • Toru Nakano
    • 1
  1. 1.Department of SurgeryKitakyushu Municipal Medical CenterKitakyushuJapan

Personalised recommendations